Q1 EPS Estimate for Cooper Companies Lowered by Analyst

The Cooper Companies, Inc. (NASDAQ:COO) – Equities researchers at William Blair dropped their Q1 2025 EPS estimates for shares of Cooper Companies in a research note issued on Monday, December 9th. William Blair analyst M. Andrew now forecasts that the medical device company will post earnings per share of $0.92 for the quarter, down from their prior estimate of $0.95. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. William Blair also issued estimates for Cooper Companies’ Q2 2025 earnings at $0.94 EPS, Q3 2025 earnings at $1.04 EPS and FY2025 earnings at $3.98 EPS.

Other research analysts have also issued reports about the company. Wells Fargo & Company upped their price target on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a report on Friday, December 6th. Stifel Nicolaus reaffirmed a “buy” rating and set a $115.00 target price (up previously from $110.00) on shares of Cooper Companies in a research report on Thursday, August 29th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research report on Friday, December 6th. Morgan Stanley dropped their price objective on shares of Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Finally, StockNews.com cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research note on Wednesday. Four analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, Cooper Companies currently has an average rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Price Performance

NASDAQ COO opened at $94.85 on Thursday. The stock has a market capitalization of $18.93 billion, a PE ratio of 48.64, a P/E/G ratio of 2.52 and a beta of 0.97. The stock has a 50-day simple moving average of $103.49 and a 200 day simple moving average of $98.87. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.12 and a current ratio of 1.91. Cooper Companies has a twelve month low of $84.76 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, December 5th. The medical device company reported $1.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.04. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.03 billion. Cooper Companies had a net margin of 10.07% and a return on equity of 9.38%. The business’s revenue was up 9.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.87 EPS.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the completion of the transaction, the chief executive officer now directly owns 165,273 shares in the company, valued at $18,267,624.69. This represents a 41.03 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 2.00% of the company’s stock.

Institutional Investors Weigh In On Cooper Companies

Large investors have recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. increased its holdings in Cooper Companies by 43.1% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 35,233 shares of the medical device company’s stock valued at $3,076,000 after purchasing an additional 10,616 shares in the last quarter. Assenagon Asset Management S.A. grew its holdings in shares of Cooper Companies by 30.9% during the second quarter. Assenagon Asset Management S.A. now owns 535,909 shares of the medical device company’s stock worth $46,785,000 after purchasing an additional 126,371 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Cooper Companies by 23.0% in the third quarter. Victory Capital Management Inc. now owns 3,950,119 shares of the medical device company’s stock valued at $435,856,000 after buying an additional 737,726 shares in the last quarter. Envestnet Asset Management Inc. increased its stake in shares of Cooper Companies by 3.7% in the second quarter. Envestnet Asset Management Inc. now owns 758,332 shares of the medical device company’s stock valued at $66,202,000 after buying an additional 26,787 shares in the last quarter. Finally, TD Asset Management Inc bought a new position in shares of Cooper Companies in the second quarter valued at about $53,045,000. Institutional investors own 24.39% of the company’s stock.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.